{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Narceine methyl ester and narceine are potent alkaloids which were isolated from Corydalis longipes were found effective in vitro at very low concentration, i.e., 100~500 ppm against spore germination of some test plant pathogenic fungi (Alternaria solani, A. tagetica, Cercospora abelmoschi, Curvularia maculans, Erysiphe cichoracearum, E. pisi, Fusarium udum, Helminthosporium oryzae, H. penniseti, Ustilago cynodontis). George Bell Frankforter was
the first person to isolate narceine (in 1893) during his Ph.D. research for August Hofmann at the University of Berlin. Narceine has a weak morphine-like action, but is not much used in medicine. It may be administered in a pill, as a mild hypnotic and to allay cough; it is less depressant than morphine and does not constipate. Ethylnarceine is a narcotic, analgesic, and antitussive.
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Ethylhydrocupreine Hydrochloride (optochin) is a reagent used in the alteration in bacterial morphology, it is now used in cell culture techniques for the presumptive identification of Streptococcus pneumoniae, which is optochin-sensitive, from other alpha-hemolytic streptococci such as viridans streptococci, which are resistant. However, a single standardized procedure does not exist. Optochin is included neither in the current EUCAST breakpoint tables nor in the CLSI performance standards for antimicrobial susceptibility testing.
Status:
US Approved Allergenic Extract
(1994)
Source:
BLA103738
(1994)
Source URL:
First approved in 1994
Source:
BLA103738
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Geraniol is a dietary monoterpene alcohol that
is found in the essential oils of aromatic plants. To date,
experimental evidence supports the therapeutic or preventive
effects of geraniol on different types of cancer, such as breast,
lung, colon, prostate, pancreatic, and hepatic cancer, and has
revealed the mechanistic basis for its pharmacological actions.
In addition, geraniol sensitizes tumor cells to commonly used
chemotherapy agents. Geraniol controls a variety of signaling
molecules and pathways that represent tumor hallmarks;
these actions of geraniol constrain the ability of tumor cells
to acquire adaptive resistance against anticancer drugs. It has been shown that geraniol inhibits
HMG-CoA reductase in most types of tumor cells, which
raises the possibility that the reduced prenylation of small
G-proteins, such as Ras or RhoA, accounts for the antitumor
effects of geraniol. In addition to its use in various commercial
products, including cosmetics and fine fragrances, geraniol
exerts a broad spectrum of pharmacological activities, such
as anti-microbial, anti-inflammatory, anti-oxidant, anti-ulcer
and neuroprotective activities. Geraniol is classified into the generally recognized-as-safe
(GRAS) category by the Flavor and
Extract Manufacturers Association (FEMA) and the Food
and Drug Administration (FDA) of the United States.
Status:
US Previously Marketed
Source:
EXKIVITY by TAKEDA PHARMS USA
(2021)
Source URL:
First approved in 2021
Source:
EXKIVITY by TAKEDA PHARMS USA
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Mobocertinib (EXKIVITY™) is a first-in-class EGFR tyrosine kinase inhibitor being developed for the treatment of EGFR exon 20 insertion (EGFRex20ins) -positive non-small cell lung cancer (NSCLC). Mobocertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that irreversibly binds to and inhibits EGFR exon 20 insertion mutations at lower concentrations than wild type (WT) EGFR. Two pharmacologically-active metabolites (AP32960 and AP32914) with similar inhibitory
profiles to mobocertinib have been identified in the plasma after oral administration of mobocertinib. In vitro, mobocertinib also inhibited the activity of other EGFR family members (HER2 and HER4) and one additional kinase (BLK) at clinically relevant concentrations (IC50 values <2 nM). Based on efficacy in patients whose disease had progressed on or after platinum-based therapy in a phase I/II trial, mobocertinib was recently granted accelerated approval in the USA in this indication. The drug is also being assessed for marketing approval in various other countries and territories including the EU and China.
Status:
US Previously Marketed
Source:
UKONIQ by TG THERAPS
(2021)
Source URL:
First approved in 2021
Source:
UKONIQ by TG THERAPS
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Umbralisib (Ukoniq, TG Therapeutics) is an orally available PI3K delta inhibitor, targeting the delta isoform with nanomolar potency and several fold selectivity over the alpha, beta, and gamma isoforms of PI3K. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-cell lymphocytes. On February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib for the following indications: adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen; adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. However, on June 1, 2022, the FDA withdrew its approval for the cancer medicine Ukoniq due to safety concerns.
Status:
US Previously Marketed
Source:
TRUSELTIQ by HELSINN HLTHCARE
(2021)
Source URL:
First approved in 2021
Source:
TRUSELTIQ by HELSINN HLTHCARE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Infigratinib (BGJ398), a potent, orally bioavailable, small-molecule pan-FGFR kinase inhibitor. FGFR genetic alterations are the most significant predictors for BGJ398 sensitivity. It is currently in phase 2 trials for Cholangiocarcinoma, Glioblastoma and Solid tumors. Detected adverse events were hyperphosphatemia, fatigue, constipation, cough and nausea. Other adverse events were generally mild and included stomatitis, hair loss, decreased appetite, and fatigue.
![Structure of 2-(4-Morpholinyl)ethyl 4-hydroxy[1,1?-biphenyl]-3-carboxylate hydrochloride](/img/bcac829b-002c-42dd-a9c0-4cfbe1dc279b.svg?size=200&context=chqyflzuvo)
